Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma

T-cell lymphoma (TCL) is resistant to conventional chemotherapy. We retrospectively evaluated the therapeutic efficiency and toxicity of gemcitabine, navelbine, and doxorubicin (GND) in patients with refractory or relapsed TCL. From 2002 to 2012, 69 patients with refractory or relapsed TCL received...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Zhengzi, Song, Zheng, Zhang, Huilai, Wang, Xianhuo, Zhao, Jing, Wang, Huaqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383323/
https://www.ncbi.nlm.nih.gov/pubmed/25866797
http://dx.doi.org/10.1155/2015/606752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383323/
https://www.ncbi.nlm.nih.gov/pubmed/25866797
http://dx.doi.org/10.1155/2015/606752

Ejemplares similares